Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod
Safura Pournajaf, Leila Dargahi, Mohammad Javan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates
Murugaiah A. M. Subbaiah, Jarkko Rautio, Nicholas A. Meanwell
Chemical Society Reviews (2024) Vol. 53, Iss. 4, pp. 2099-2210
Closed Access | Times Cited: 24
Neuroinflammation and Epilepsy: From Pathophysiology to Therapies Based on Repurposing Drugs
Pascual Sanz, Teresa Rubio, María Adelaida García-Gimeno
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4161-4161
Open Access | Times Cited: 10
Sphingolipid metabolism and signaling in cardiovascular diseases
Sonia Borodzicz-Jażdżyk, Piotr Jażdżyk, Wojciech Łysik, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 30
Glycyrrhizin as a potential disease-modifying therapy for epilepsy: insights into targeting pyroptosis to exert neuroprotective and anticonvulsant effects
Lei Wei, Sijie Ou, Youshi Meng, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury
Qi Shi, Tingting Hu, Lixia Xu, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 2229-2245
Open Access
Challenges and opportunities for repairing the injured spinal cord: inflammation, regeneration, and functional reconstruction
Xiaowei Zha
Regenerative medicine reports . (2025) Vol. 2, Iss. 1, pp. 36-44
Closed Access
Plant-based production of an orally active cyclotide for the treatment of multiple sclerosis
Mark A. Jackson, Jing Xie, Linh T. T. Nguyen, et al.
Transgenic Research (2023) Vol. 32, Iss. 1-2, pp. 121-133
Open Access | Times Cited: 14
Inflammation, Anti-inflammatory Interventions, and Post-stroke Cognitive Impairment: a Systematic Review and Meta-analysis of Human and Animal Studies
Reinier Tack, Claudia Amboni, Danny van Nuijs, et al.
Translational Stroke Research (2023)
Open Access | Times Cited: 12
The Role of Sphingomyelin and Ceramide in Motor Neuron Diseases
Gavin McCluskey, Colette Donaghy, Karen Morrison, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 9, pp. 1418-1418
Open Access | Times Cited: 21
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Volkmar Leßmann, Georgia-Ioanna Kartalou, Thomas Endres, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 8, pp. 1003-1012
Open Access | Times Cited: 10
Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders
Fatemeh Rahmati‐Dehkordi, Hadi Khanifar, Nazanin Najari, et al.
Neurochemical Research (2024) Vol. 49, Iss. 10, pp. 2668-2681
Closed Access | Times Cited: 3
Fingolimod effects on the brain are mediated through biochemical modulation of bioenergetics, autophagy, and neuroinflammatory networks
Mehdi Mirzaei, Morteza Abyadeh, A Turner, et al.
PROTEOMICS (2022) Vol. 22, Iss. 19-20
Open Access | Times Cited: 17
Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
Siyao Li, Koki Sakurai, Masahiro Ohgidani, et al.
Molecular Brain (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis
Tarun Kapoor, Sidharth Mehan, Manisha Suri, et al.
Cells (2022) Vol. 11, Iss. 18, pp. 2771-2771
Open Access | Times Cited: 15
Genetics and epigenetics of rare hypersomnia
Maria P. Mogavero, Lourdes M. DelRosso, Oliviero Bruni, et al.
Trends in Genetics (2023) Vol. 39, Iss. 5, pp. 415-429
Closed Access | Times Cited: 8
Pharmacological Effects of FTY720 and its Derivatives
Mengyuan Han, Xiangran Liu, Sendaer Hailati, et al.
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 3, pp. 192-200
Closed Access | Times Cited: 2
Fingolimod exerts neuroprotection by regulating S1PR1 mediated BNIP3-PINK1-Parkin dependent mitophagy in rotenone induced mouse model of Parkinson's disease
Shruti Rajan, Anika Sood, Rachit Jain, et al.
Neuroscience Letters (2023) Vol. 820, pp. 137596-137596
Closed Access | Times Cited: 7
Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis
Yasuyuki Kihara, Jerold Chun
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108432-108432
Open Access | Times Cited: 5
Glial modulators as novel therapeutics for comorbid pain and opioid use disorder
Elizabeth Schwartz, João P. De Aquino, Mehmet Sofuoglu
British Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 1
Isolation and Characterization of the Cyanobacterial Macrolide Glycoside Moorenaside, an Anti-Inflammatory Analogue of Aurisides Targeting the Keap1/Nrf2 Pathway
Fatma H. Al‐Awadhi, Sofia Kokkaliari, Ranjala Ratnayake, et al.
Journal of Natural Products (2024)
Open Access | Times Cited: 1
Fingolimod Inhibits C6 Rat Glioma Proliferation and Migration, Induces Sub‐G1 Cell Cycle Arrest, Mitochondrial and Extrinsic Apoptosis In Vitro and Reduces Tumour Growth In Vivo
Sanaz Pournajaf, Nastaran Afsordeh, Hadi Bayat, et al.
Clinical and Experimental Pharmacology and Physiology (2024) Vol. 52, Iss. 1
Closed Access | Times Cited: 1
Discovery and Anti-Inflammatory Activity of a Cyanobacterial Fatty Acid Targeting the Keap1/Nrf2 Pathway
Fatma H. Al‐Awadhi, Emily F. Simon, Na Liu, et al.
Marine Drugs (2023) Vol. 21, Iss. 11, pp. 553-553
Open Access | Times Cited: 4
N-Containing triterpenoid saponins from Mussaenda densiflora and identification of heinsiagenin A as a potent immunosuppressant
Xiuying Du, Dilinaer Litifu, Wenlong Yuan, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107351-107351
Closed Access
Senotherapeutic Peptide 14 Suppresses Th1 and M1 Human T Cell and Monocyte Subsets In Vitro
Thuany Alencar‐Silva, Stefhani Martins de Barcelos, Amandda É. Silva‐Carvalho, et al.
Cells (2024) Vol. 13, Iss. 10, pp. 813-813
Open Access
Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database
Xiping Yang, Yan Yan, Suyao Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Page 1 - Next Page

Scroll to top